|
Hutchmed China Ltd on Wednesday said the results from its SACHI phase-three lung cancer trial have been published in medical journal the Lancet. Hutchmed China explained that the study looked at savolitinib and osimertinib in combination for the treatment of ‘locally advanced or metastatic epidermal growth factor receptor mutation-positive non-small cell lung cancer with MET amplification after disease progression on first-line EGFR tyrosine kinase inhibitor therapy’. MET is a tyrosine kinase receptor that has an essential role in normal cell development, said Hutchmed China. The Hong Kong-based developer of treatments for cancer and immunological diseases said savolitinib is an oral, potent and highly selective MET TKI. It is being jointly developed by Hutchmed and Cambridge, England-based pharmaceutical company AstraZeneca PLC, and commercialised by AstraZeneca. Osimertinib is a third-generation, irreversible EGFR TKI, added Hutchmed China. The company said the study was the first randomised phase three trial that confirmed the efficacy of MET inhibition in patients with ‘advanced NSCLC and acquired MET amplification after progression on prior EGFR-TKI treatment’. Hutchmed China said interim data from the trial led to the combination being approved in China in June last year. Shares in Hutchmed China were down 0.5% at 220.00 pence around midday on Wednesday in London. ‘The SACHI trial, now published in The Lancet, provides compelling evidence that savolitinib combined with osimertinib can transform outcomes for patients with EGFR-mutated NSCLC with MET amplification. These findings highlight the combination’s ability to address MET amplification, a critical resistance mechanism, offering clinically meaningful improvements for this challenging patient population,’ said Shun Lu, chief of the Shanghai Lung Cancer Center at Shanghai Chest Hospital, School of Medicine, Shanghai Jiaotong University, and co-leading Principal Investigator of the SACHI trial. Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
